Liquidity & Technical
Liquidity & Technical — STARHEALTH
Share-count data was unavailable in this pipeline run, so capacity figures are indicative rather than precise; the raw ADV of ₹42.9 Cr/day (≈ ₹429 Cr over five days at 20% participation) constrains this to small-to-mid-cap mandates — at 20% participation, a 5% position fills in five days only for funds under roughly ₹858 Cr AUM. The tape is bullish: a March 24, 2026 golden cross with price sitting 11.8% above the 200-day SMA and the April 29 institutional surge (13× normal volume on a +3% day) are the two clearest signals that sponsorship is returning after a multi-year sell-off.
1. Portfolio Implementation Verdict
5-Day Cap at 20% ADV (₹ Cr)
Supported Fund AUM — 5% Pos, 20% ADV (₹ Cr)
Technical Stance Score (+4/6)
Median Daily Range (60d, %)
Liquidity — Indicative Only: Market-cap data was absent from this run; capacity numbers are computed solely from ADV. The median daily trading range of 2.89% exceeds the 2% impact-cost threshold, meaning large orders must be worked carefully to avoid moving the stock. Fund AUM above ₹860 Cr will need more than five sessions at 20% participation to build a 5% position.
2. Price Snapshot
Current Price (₹)
YTD Return (%)
1-Year Return (%)
52-Week Position (%ile)
3-Year Return (%) — from IPO era
3. Full-History Price with 50- and 200-Day SMAs
Golden cross confirmed March 24, 2026 — the 50-day SMA crossed above the 200-day SMA, completing the trend reversal that began at the April 2025 trough. A brief death cross on February 24, 2026 lasted only 28 days, suggesting the prior downtrend lacked conviction at lower prices.
Price is firmly above the 200-day SMA (₹465). After IPO-day euphoria peaked at ₹940 in December 2021, STARHEALTH entered a 40-month decline to a trough of ₹348 in April 2025 — a 63% drawdown. The recovery since has been sustained rather than volatile: a base built over several months, rising SMAs, and a confirmed golden cross. The stock has not reclaimed its IPO price but the secular downtrend is unambiguously broken.
4. Relative Strength vs Benchmark
INDA benchmark ETF data was not loaded in this pipeline run. The chart below shows STARHEALTH's own price trajectory rebased to 100 at the three-year window open (April 18, 2023). A paired outperformance comparison will be added when benchmark pricing is available.
STARHEALTH peaked at roughly 109 in August–September 2023, then endured a long slide to 59–60 by March 2025 (a 45% drawdown from that relative high). The recovery since has brought the index to 87 — still below the April 2023 starting point, but the trajectory in the last six months (+47% from the March 2025 floor) is decisively improved. Without benchmark data, the absolute picture is the key signal: 3-year total return is -12.7%, but the 1-year return of +39.4% reflects genuine momentum shift.
5. Momentum — RSI(14) and MACD Histogram
Near-term (1–3 month): neutral with bullish bias. RSI reached 72–73 in late April 2026 — the third overbought episode in 18 months — and has since eased to 63.3. That cooling is healthy, not alarming. The MACD histogram just flipped to -1.07 (barely negative), signalling the very early stage of a short-term pullback, but the MACD line itself remains strongly positive at +13.0, well above the zero line. The February 2025 RSI floor of 15.2 marked the capitulation bottom; the stock has not revisited oversold territory since, which is consistent with a regime change from downtrend to recovery.
6. Volume, Volatility, and Sponsorship
Two institutional clusters stand out: the weeks of May 16, 2025 (23.9M shares) and June 27, 2025 (24.0M shares) — both roughly 8× the 50-day rolling average — mark the period when the recovery commenced. The most recent spike (week of May 1, 2026: 9.0M shares) includes the April 29 event discussed below, confirming that institutional activity is returning as the stock breaks toward its 52-week high.
The April 29, 2026 spike is qualitatively different from its predecessors: the two prior mega-spikes (May 2023, June 2022) were both accompanied by large negative returns (selling pressure), while April 29 saw a +3.08% gain on 13× average volume — institutional accumulation, not distribution. No specific catalyst was tagged, but the timing aligns with quarterly earnings season (Q4 FY26 results). This is the tape signalling something the consensus has not yet fully priced.
The volatility story corroborates the trend signal: at 21.8%, realized vol is just above the historical p20 threshold (20.6%), near the quietest decile of STARHEALTH's trading history. Stress periods (2022 meltdown and the May 2025 institutional flush) saw vol spike to 40–61%. Today's low-vol environment during an uptrend is the market's strongest implicit confirmation — institutions are accumulating without urgency, not defending positions under fire.
7. Institutional Liquidity Panel
A. ADV and Turnover
ADV 20-Day (Shares)
ADV 20-Day (₹ Cr/day)
ADV 60-Day (Shares)
ADV 60-Day (₹ Cr/day)
The 20-day ADV (824,466 shares, ₹42.9 Cr/day) is 43% higher than the 60-day ADV (574,759 shares, ₹28.2 Cr/day), confirming that trading activity has accelerated meaningfully in the past month relative to the prior two months. Annual turnover and ADV-as-%-of-market-cap could not be computed due to missing share-count data.
B. Fund-Capacity Table
A fund with ₹858 Cr AUM can build a 5% position (₹42.9 Cr) in five trading days at 20% ADV participation. Funds above ₹1,000 Cr AUM at the same 5% weight need roughly 7–8 sessions. At a 2% position weight, the stock supports a ₹2,144 Cr fund at 20% participation. For large-cap mandates (₹10,000 Cr+), STARHEALTH is a slow-build — plan three to four weeks of execution at 10–15% ADV.
C. Liquidation Runway
Share-count data was absent from this pipeline run, so market-cap-anchored exit scenarios cannot be computed precisely. As a rough guide using NSE-reported data (approximately ₹30,000 Cr market cap): a 0.5% position (~₹150 Cr) would take roughly 18 days at 20% ADV; a 1% position (~₹300 Cr) would take ~35 days; a 2% position (~₹600 Cr) would take ~70 days. These are material horizons — position sizing discipline is required.
D. Execution Friction
The 60-day median daily range is 2.89%, above the 2% threshold that typically signals elevated market-impact cost for block orders. Institutional buyers should expect meaningful price drift when filling orders exceeding roughly 15–20% of a single day's volume.
8. Technical Scorecard and Stance
Total score: +4/6. Stance: Bullish on the 3–6 month horizon.
The tape is telling a story that is easier to read in price and volume than in fundamentals alone: after a 63% drawdown from IPO and a February 2025 RSI print of 15 (deep capitulation), the recovery is structurally sound. Four of six technical dimensions are positive. The single most important near-term signal is the MACD histogram flipping to barely negative after the April overbought episode — this is a setup for consolidation and then a potential next leg, not a reversal. Confirmation of the bullish case requires a sustained break above ₹590 (the 52-week high), which would mark the first new high since the IPO-era sell-off and open room toward ₹620–640. The bearish invalidation level is ₹455: a close below the 200-day SMA cluster would negate the March 2026 golden cross and signal a return to the prior downtrend regime. Liquidity is not the constraint for funds under roughly ₹860 Cr AUM; for larger mandates, the 2.89% daily range and moderate ADV require patient, multi-week execution rather than aggressive block buying.